NCT02416232.

Study name	An open label non randomized access study of trametinib for patients with advanced unresectable (stage IIIc) or distant metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma.
Methods	Phase III non‐RCT.
Participants	Metastatic melanoma with brain metastasis. Estimated enrolment: 250.
Interventions	Single arm study: participants will receive trametinib 2 mg orally once daily and, where appropriate, in combination with dabrafenib 150 mg orally twice daily.
Outcomes	Primary outcomes: Frequency of adverse events (AE); Proportion of the AEs; Number of participants with serious adverse events (SAEs); and Response rates to treatment
Starting date	March 2015.
Contact information	USA GSK Clinical Trials Call Center, GSKClinicalSupportHD@gsk.com
Notes	‐